EFTA00300337Set 9
2014-05-229p5,425w
Overweight ►aces
ua
Gilead Sciences GILD, GILD US
Price: $81.81
Thoughts on the RSV Space: Sales Could Top $2B
Price Target: $100.00
Although Gilead's hepatitis C franchise ... hepatitis B,
Geoff Meacham AC
NASH, IPF, hematology/oncology and now respiratory syncytial virus (RSV).
Indeed, at the ATS meeting this week, Gilead revealed phase 2a data ... RSV. In this report, we review the data, the therapeutic landscape and Bloomberg JPMA AIEACHAM <GO,
the opportunity in RSV including feedback we've received from several Michael
https://www.justice.gov/epstein/files/DataSet%209/EFTA00300337.pdf
EFTA01687250Set 10
2019-08-15118p16,338w
M143968-5C3
G) k 489
EFTA01687319
,v. I OP,
a.t.
Ce
•
S:
;
A'
I RSV °
/ , n,•t at t , OK e
Metropolitan Correctional Center New York, N.Y.
Photo Sheet
Lieutenant
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01687250.pdf